Home › Diffuse Large B-Cell Lymphoma › Kansas
Pag-aaral pangklinika para sa Diffuse Large B-Cell Lymphoma sa Kansas
7 pag-aaral para sa Diffuse Large B-Cell Lymphoma ang naghahanap ng mga kalahok sa mga site sa Kansas.
Opisyal na teksto ng pag-aaral (English)
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
- Cotton O'Neil Cancer Center ( Site 0108), Topeka
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT06717347A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
- University of Kansas Cancer Center, Kansas City
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Set 22, 2026 · NCT07101328Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU
- University of Kansas Cancer Center, Westwood
Nagre-recruitObservasyonal na pag-aaral
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 5, 2026 · NCT06116110A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
- University of Kansas Cancer Center, Westwood
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 4, 2026 · NCT07188558DALY II USA/ MB-CART2019.1 for DLBCL
- University of Kansas Cancer Center, Westwood
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 13, 2026 · NCT04792489SynKIR-310 for Relapsed/Refractory B-NHL
- The University of Kansas Cancer Center, Fairway
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Abr 14, 2026 · NCT06544265Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
- University of Kansas Cancer Center, Kansas City
- University of Kansas Cancer Center-Overland Park, Overland Park
- University of Kansas Hospital-Westwood Cancer Center, Westwood
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Peb 2, 2026 · NCT05633615Mula sa ClinicalTrials.gov, na-kuha noong Set 30, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.